What are the EULAR guidelines on the use of anti–TNF-alpha agents by pregnant women with rheumatoid arthritis (RA)?

Updated: May 11, 2018
  • Author: Katherine K Temprano, MD; Chief Editor: Christine Isaacs, MD  more...
  • Print
Answer

Answer

The EULAR guidelines make the following recommendations for use of anti-TNF medications [18] :

  • Infliximab/adalimumab:  Can be continued up to 20 weeks gestation; if indicated, it can be used throughout pregnancy, based on current evidence indicating no increased rate of congenital malformations 
  • Golimumab: Because of limited evidence, alternative medications should be considered for treatment throughout pregnancy
  • Etanercept: Can be continued up to 30–32 weeks of gestation; if indicated, it can be used throughout pregnancy, based on current evidence indicating no increased rate of congenital malformations 
  • Certolizumab: Can be used throughout pregnancy, based on current evidence indicating no increased rate of congenital malformations

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!